Corrigendum to “Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention” [Pharmacol. Res. 129 (2018) 216–226]

Molecular design of multitarget neuroprotective agents 5. Modification with pharmacologically active fragments of 4,4- and 1,4-dipropargyl-5-methyl-2-phenylpyrazol-3-one

“…Earlier, we have proposed various options for modifi cation of biologically active structures with additional pharmacophores expanding the spectrum of biological activity of the target structures. [7][8][9] In the present work, we describe the conjugation of the drug Edaravone (1) with various pharmacologically active fragments based on bispropargylation of compound 1 and the subsequent click-reaction of copper-catalyzed alkyne-azide 1,3-dipolar cycloaddition in order to design new potential multitarget drugs for treatment of neurodegenerative diseases. The chosen farmacoactive fragments include 1-aminoadamantane derivatives, the known drugs for treatment of neurodegenerative diseases Amantadine and Memantine, carbazole and tetrahydrocarbazole derivatives, a heterocyclic base, for example, of the drug Carprofen, and tetrahydro-γ-carboline derivatives, a fragment of the known drugs Diazolin and Dimebon, as well as many representatives of neuroprotectors.…”